Advertisement
Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment
(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday that it has completed bioanalytical method development under its prior agreement with Altasciences.
The company now plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University.
The blood and plasma samples collected are part of a dose response study in a humanized mouse model.
The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.
read more
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews
|
726天前
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.
RTTNews
|
982天前
Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
RTTNews
|
1082天前
Sensex, Nifty End Choppy Session Little Changed
Indian shares fluctuated before ending little changed on Friday despite GST reforms optimism and firm cues from global markets amid growing expectations of a Federal Reserve interest-rate cut later this month.
RTTNews
|
1天前
European Shares Inch Higher In Cautious Trade
European stocks were modestly higher on Friday as investors braced for the key U.S. jobs reading due later in the day and French Prime Minister Francois Bayrou's confidence vote on Monday.
RTTNews
|
1天前
Asian Shares Modestly Higher Before Pivotal US Jobs Report
Asian stocks eked out modest gains on Friday as weak U.S. labor market data reinforced expectations of a Federal Reserve rate cut later this month and U.S. President Donald Trump signed an executive order officially putting into action the U.S.-Japan trade agreement.
RTTNews
|
1天前
European Shares Set For Steady Open Before US Jobs Report
European stocks may open slightly higher on Friday as investors await the all-important monthly U.S. jobs report later in the day for direction.
RTTNews
|
2天前
Sensex, Nifty Open Higher On Fed Rate Cut Hopes
Indian shares were modestly higher on Friday as weak U.S. labor market data fueled fresh hopes for a Federal Reserve rate cut this month.
RTTNews
|
2天前
